Scotiabank initiated coverage of Vera Therapeutics with an Outperform rating and $60 price target The firm sees “plenty of value-creating catalysts” in the near- to medium-term as Vera reports pivotal data for its dual APRIL/BAFF inhibitor, atacicept, in IgA nephropathy and approaches potential commercialization. Its key opinion leader checks have indicated a “strong desire” to prescribe atacicept when it potentially becomes available. This can drive rapid uptake at launch, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Vera Therapeutics Expands Atacicept Autoimmune Kidney Studies
- Vera Therapeutics to expand development pipeline for atacicept
- Vera Therapeutics to report results from ORIGIN Phase 2b clinical trial
- Vera Therapeutics completes enrollment for Phase 3 ORIGIN 3 trial of atacicept
- JPMorgan ups Vera Therapeutics target, adds Analyst Focus List